NCT01743482

Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors

Phase II Study of Single-agent Pazopanib (Votrient®) for Patients With Relapsed or Refractory Germ-cell Tumors (GCT).

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 43 (actual)
• Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Academic / Other
• Sex: Male
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an open label, single arm, single center, phase 2 study with the use of the antiangiogenic multikinase inhibitor pazopanib in a population of patients with germ cell tumors who are not cured following first or subsequent chemotherapy lines for metastatic disease, followed by eventual surgery.

Conditions

• Germ Cell Tumors
• Measurable Disease

Interventions

Type	Name	Description
DRUG	Pazopanib

Timeline

• Start date: 2013-05-17
• Primary completion: 2016-07-27
• Completion: 2016-07-27
• First posted: 2012-12-06
• Last updated: 2021-05-14

Locations

1 site across 1 country: Italy